Yayın:
Lip Mesotherapy With Dexpanthenol As A Novel Approach To Prevent Isotretinoin-Associated Cheilitis

dc.contributor.authorÇağrı Turan
dc.contributor.authorÜmran Öner
dc.date.accessioned2026-01-04T18:22:46Z
dc.date.issued2023-01-31
dc.description.abstractIntroduction: Isotretinoin (ISO)-associated cheilitis is the most common side effect and the most common reason for discontinuation of ongoing therapy. So, various lip balms are also routinely recommended for all patients. Objectives: We aimed to investigate the effectiveness of local intradermal injections (mesotherapy) of dexpanthenol into the lips to prevent ISO-associated cheilitis. Methods:  This pilot study was conducted on patients over the age of 18 using ISO (about 0.5 mg/kg/day). All patients were prescribed only hamamelis virginiana distillate in ointment form as a lip balm. In the mesotherapy group (n=28), 0.1 ml of dexpanthenol was injected into each lip tubercle (4 points total) to the submucosal level. The patients in the control group (n=26) used only the ointment. “ISO cheilitis grading scale (ICGS)” was used in the evaluation of ISO-associated cheilitis. The patients were followed for 2 months. Results:  Although there was an increase in ICGS scores in the mesotherapy group compared to the baseline, no statistically significant change was observed after treatment (p=0.545). However, in the control group, there was a statistically significant increase in ICGS scores in the 1st and 2nd months compared to the baseline (p<0.001). Lip balms were needed significantly less frequently in the mesotherapy group compared to the control, both in the 1st and 2nd months (p=0.006, p=0.045; respectively). Conclusions: Lip mesotherapy with dexpanthenol will be a useful option for preventing ISO-associated cheilitis because of its easy application, cost-effectiveness, low complication risk, and high patient satisfaction.
dc.description.urihttps://doi.org/10.5826/dpc.1301a12
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/36892384
dc.description.urihttp://dx.doi.org/10.5826/dpc.1301a12
dc.description.urihttps://doaj.org/article/b8f76aaf3b694095983a0c8c03af0909
dc.identifier.doi10.5826/dpc.1301a12
dc.identifier.eissn2160-9381
dc.identifier.openairedoi_dedup___::06ef81e7ecbf41a0ffb1b0b7b3d9362f
dc.identifier.orcid0000-0002-6111-4314
dc.identifier.pubmed36892384
dc.identifier.scopus2-s2.0-85160422449
dc.identifier.startpagee2023012
dc.identifier.urihttps://hdl.handle.net/20.500.12597/40492
dc.identifier.wos001015300600026
dc.publisherMattioli1885
dc.relation.ispartofDermatology Practical & Conceptual
dc.rightsOPEN
dc.subjectdexpanthenol
dc.subjectmesotherapy
dc.subjectcheilitis
dc.subjectRL1-803
dc.subjectmucocutaneous side effect
dc.subjectisotretinoin
dc.subjectOriginal Article
dc.subjectDermatology
dc.subject.sdg3. Good health
dc.titleLip Mesotherapy With Dexpanthenol As A Novel Approach To Prevent Isotretinoin-Associated Cheilitis
dc.typeArticle
dspace.entity.typePublication
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar